“Benson Hill is dedicated to delivering highly efficient and fully accessible product development solutions for our partners,” said Matthew Crisp, CEO, and co-founder of Benson Hill Biosystems. “We’re excited about this first patent issuance relating to our CRISPR 3.0 nuclease portfolio, and we are excited to move forward with commercial and research applications of this technology. We will continue to pursue filings for a pipeline of technologies and applications that provide choice, clarity, and confidence to our partners.”
Benson Hill’s genome editing system Edit, powered by CropOS, is designed to optimize plant characteristics such as flavor profiles, nutrient-density, and environmental sustainability. The company will continue to make CRISPR 3.0 freely available for research purposes among the academic and not-for-profit communities.